Fenofibrate Contraindication and Management in End‑Stage Renal Disease (ESRD)

Guideline Recommendations

The American College of Cardiology/American Heart Association (ACC/AHA) guidelines assign a Class III: Harm recommendation to fenofibrate in patients with moderate or severe renal impairment (eGFR < 30 mL/min/1.73 m²), making its use absolutely contraindicated in ESRD (eGFR < 15 mL/min/1.73 m² or dialysis dependence). 1
The Kidney Disease Outcomes Quality Initiative (KDOQI) 2012 guidelines explicitly advise avoiding fenofibrate in CKD stages 4‑5 and in kidney‑transplant recipients. 2

Renal elimination of fenofibrate leads to drug accumulation in severe renal impairment, markedly increasing the risk of rhabdomyolysis—especially when combined with statins. (Guideline‑based safety warning) 1
Case reports have documented severe rhabdomyolysis requiring plasma exchange in ESRD patients even after dose reduction, confirming that dose lowering does not mitigate toxicity. (Clinical observation) 1

CKD Stage	eGFR (mL/min/1.73 m²)	Fenofibrate Recommendation
4‑5	< 30	Avoid
3b‑3a	30‑59	Dose reduction (e.g., 54 mg/day) – not applicable to ESRD
≥ 2	≥ 60	Standard dosing (if indicated)

Source: KDOQI 2012 dosing recommendations 3

Omega‑3 fatty‑acid supplementation is recommended as a safer option for severe hypertriglyceridemia (triglycerides > 500 mg/dL) in ESRD patients. 4
Gemfibrozil at a reduced dose (≈ 600 mg daily) may be considered only when absolutely necessary, acknowledging limited supporting data. 3
Statins remain the preferred agents for LDL‑cholesterol lowering in ESRD, with proven cardiovascular benefit, although efficacy is attenuated in dialysis populations. 2
Statin dosing must be adjusted for ESRD (e.g., rosuvastatin maximum 5 mg daily). 3

Dose reduction of fenofibrate (e.g., to 54 mg/day) is permissible for patients with eGFR 30‑59 mL/min/1.73 m² but must not be applied to ESRD; fenofibrate is absolutely contraindicated regardless of dose. 5

The American College of Cardiology explicitly states fenofibrate must be discontinued if eGFR persistently decreases to <30 mL/min/1.73m² during treatment 6
The KDOQI guidelines emphasize that fenofibrate is contraindicated in advanced CKD and should not be used in kidney transplant recipients 7

Gemfibrozil plus statin is absolutely contraindicated due to markedly increased risk of rhabdomyolysis 6
Fenofibrate may be considered with low- or moderate-intensity statins only if benefits outweigh risks, but this combination carries increased risk of muscle toxicity 6, 8
The American Diabetes Association states statin-fibrate combination therapy has not shown cardiovascular benefit and is generally not recommended 8

In patients with moderate renal impairment (eGFR 30-59 mL/min/1.73m²), the dose of fenofibrate should be reduced to a maximum of 54 mg/day 6, 9
Intensive monitoring is required in patients with moderate renal impairment, including renal function assessment before initiation, within 3 months, and then every 6 months 6, 10

Assess both serum creatinine and eGFR before starting fenofibrate, and recheck within 3 months of initiation and every 6 months thereafter 6, 10
Obtain baseline hepatic transaminases before initiation and monitor liver function tests as clinically indicated during treatment 6, 10
Discontinue fenofibrate if persistent ALT elevations ≥3 times upper limit of normal occur 6

The American College of Cardiology recommends against the use of fenofibrate in patients with severe renal impairment, including those receiving dialysis, due to the risk of severe drug accumulation and elevated risk of rhabdomyolysis, particularly if statins are co-administered 11

For severe hypertriglyceridemia, the American College of Cardiology suggests prioritizing therapeutic lifestyle modifications and considering omega-3 fatty acids as an alternative to fibrates, with consultation of nephrology and lipid specialists for alternative strategies 11